EOM Pharmaceutical Holdings, Inc. (IMUC)
(Delayed Data from OTC)
$0.19 USD
-0.01 (-4.52%)
Updated Jun 13, 2024 03:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
EOM Pharmaceutical Holdings, Inc. [IMUC]
Reports for Purchase
Showing records 1 - 20 ( 90 total )
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for IMUC
Provider: ValuEngine, Inc
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Positive SNO Updates and Reverse Split; Target Adjusted to $5
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; Some More Hurdles To Jump; Target to $0.20
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: Inaugural Healthcare Monthly; Catalysts Galore
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Results; Long-Term Play With Promise; Adjusting Target to $0.70
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; Site Activation Continues for Phase III
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; ''107 Phase III Started and Looking to Stem-to-T Visibility
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Final Phase II Data Pave Path; Phase III Paid For
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Results; Phase III Is Screening and Funded
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J